Disc Medicine (IRON) CCO awarded 17,000 RSUs and 25,500 options

Rhea-AI Filing Summary

Disc Medicine’s Chief Commercial Officer Pamela Stephenson reported equity awards that increase her direct ownership stake. On February 10, 2026, she acquired 17,000 shares of common stock as restricted stock units at a grant price of $0, bringing her directly held common shares to 86,529.

She also received a stock option for 25,500 shares with an exercise price of $74.75 per share. The RSUs vest in four annual 25% installments starting February 15, 2027, and the option vests in 48 equal monthly installments starting March 10, 2026, in each case subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Stephenson Pamela

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,500	$0.00	--
Grant/Award	Common Stock	17,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,500 shares (Direct); Common Stock — 86,529 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stephenson Pamela

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		17,000(1)	A	$0	86,529	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$74.75	02/10/2026		A		25,500		(2)	02/09/2036	Common Stock	25,500	$0	25,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option vest in 48 equal monthly installments commencing on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRON’s Chief Commercial Officer report?

Pamela Stephenson reported receiving equity awards from Disc Medicine. She was granted 17,000 restricted stock units and a stock option for 25,500 shares, both on February 10, 2026, increasing her directly held common stock to 86,529 shares after the grants.

How many Disc Medicine (IRON) shares did Pamela Stephenson acquire?

She acquired 17,000 restricted stock units and an option covering 25,500 shares. The RSUs represent common stock granted at $0, while the option allows future purchase of 25,500 shares at a $74.75 exercise price, subject to vesting and continued service conditions.

At what price were the Disc Medicine equity awards granted to the CCO?

The 17,000 restricted stock units were granted at $0, reflecting a stock-based award rather than a cash purchase. The 25,500-share stock option has a $74.75 exercise price, meaning that amount must be paid per share when exercising the option after vesting.

How do the IRON restricted stock units granted to the CCO vest?

The 17,000 restricted stock units vest in four equal 25% installments. Vesting begins on February 15, 2027 and then annually, provided Pamela Stephenson continues to serve the company on each vesting date, aligning her incentives with longer-term company performance.

What is the vesting schedule for the Disc Medicine stock options?

The stock option for 25,500 shares vests in 48 equal monthly installments. Vesting starts on March 10, 2026, and continues monthly, conditioned on Pamela Stephenson’s continued service, gradually increasing the number of exercisable option shares over a four-year period.

What is Pamela Stephenson’s Disc Medicine share ownership after these grants?

Following the reported transactions, she directly beneficially owns 86,529 shares of Disc Medicine common stock. This total reflects the addition of 17,000 newly granted restricted stock units, which convert into common shares as they vest over the four-year schedule.